(Q44953760)

English

Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

7 December 2017

Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial (English)

1 reference

Europe PubMed Central

7 December 2017

0 references

metabolic syndrome

1 reference

based on heuristic

inferred from title

multicenter clinical trial

1 reference

based on heuristic

inferred from title

(RS)-rosiglitazone

1 reference

based on heuristic

inferred from title

Giuseppe Derosa

1

1 reference

Europe PubMed Central

7 December 2017

Arrigo F. Cicero

2

1 reference

Europe PubMed Central

7 December 2017

5

1 reference

Europe PubMed Central

7 December 2017

Pietro D Ragonesi

4

object named as

Pietro D Ragonesi

1 reference

Europe PubMed Central

7 December 2017

Leonardina Ciccarelli

7

object named as

Leonardina Ciccarelli

1 reference

Europe PubMed Central

7 December 2017

Mario N Piccinni

8

object named as

Mario N Piccinni

1 reference

Europe PubMed Central

7 December 2017

Antonio Vittorino Gaddi

3

object named as

Antonio Gaddi

1 reference

Europe PubMed Central

7 December 2017

Gianandrea Bertone

6

object named as

Gianandrea Bertone

1 reference

Europe PubMed Central

7 December 2017

publication date

1 May 2004

1 reference

Europe PubMed Central

7 December 2017

Clinical Therapeutics

1 reference

Europe PubMed Central

7 December 2017

26

1 reference

Europe PubMed Central

7 December 2017

5

1 reference

Europe PubMed Central

7 December 2017

744-754

1 reference

Europe PubMed Central

7 December 2017

Rationale and options for combination therapy in the treatment of Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990074-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Combining sulfonylureas and other oral agents

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990074-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Sulfonylurea stimulation of insulin secretion

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990074-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical review of glimepiride

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990074-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Thiazolidinediones -- some recent developments

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990074-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990074-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Addressing the insulin resistance syndrome: a role for the thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990074-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990074-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990074-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990074-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990074-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990074-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The Glycosylation of Hemoglobin: Relevance to Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990074-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Determination of total serum insulin (IRI) in insulin-treated diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990074-4

7 January 2021

based on heuristic

inferred from DOI database lookup

THE DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUM

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990074-4

7 January 2021

based on heuristic

inferred from DOI database lookup

An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990074-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990074-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990074-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990074-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Glimepiride in type 2 diabetes mellitus: a review of the worldwide therapeutic experience

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990074-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of glimepiride on HbA(1c) and body weight in Type 2 diabetes: results of a 1.5-year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990074-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Glitazones: clinical effects and molecular mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990074-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990074-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Thiazolidinediones and blood lipids in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990074-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990074-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990074-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0149-2918(04)90074-4

1 reference

Europe PubMed Central

7 December 2017

1 reference

Europe PubMed Central

7 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44953760&oldid=2059447956"